- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Medical Bulletin 02/April/2026 - Video
Overview
Here are the top medical news for today:
Experimental Cancer Drug Reduces Deadly Brain Tumor Within Days, Study Shows Promising Results
A groundbreaking study from Mass General Cancer Center, published in The New England Journal of Medicine, reports promising early results for a novel CAR-T cell therapy targeting Glioblastoma. The phase 1 INCIPIENT Trial evaluated an experimental treatment called CARv3-TEAM-E T cell therapy in patients with recurrent disease.
Glioblastoma is one of the most aggressive brain tumors, with poor survival rates and limited treatment options. Standard approaches—surgery, radiation, and chemotherapy—often fail due to tumour heterogeneity, where cancer cells vary widely within the same tumor, making targeted therapies less effective.
CAR-T Cell Therapy works by modifying a patient’s own T cells to recognize and attack cancer cells. While successful in blood cancers, its application in solid tumors like glioblastoma has been challenging. This new approach aims to overcome those barriers.
In the study, three patients aged 57 to 74 received the therapy after standard treatments had failed. All showed rapid tumor reduction. One patient experienced near-complete tumor disappearance within five days. Another had over 60% tumor shrinkage lasting more than six months, while the third showed significant but temporary improvement. Although tumors eventually progressed in all cases, the speed and magnitude of response mark a major advance.
The treatment was generally well tolerated, with manageable side effects such as fever and temporary neurological symptoms. Patients were closely monitored and safely discharged.
Researchers are now focused on improving durability through strategies like repeated infusions, combination therapies, and enhancing T cell persistence.
While still experimental, this therapy represents a significant step forward. It offers new hope for patients with glioblastoma and may pave the way for more effective, personalized cancer treatments in the future.
REFERENCE: Bryan D. Choi, Elizabeth R. Gerstner, et al.; Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma; The New England Journal of Medicine; DOI: 10.1056/NEJMoa2314390
Study Explores How Vitamin D in First 1,000 Days Shapes Lifelong Health Outcomes
A recent review published in Nutrients explores the role of Vitamin D during the first 1,000 days of life, using the Developmental Origins of Health and Disease approach. This critical window—from pregnancy to early childhood—is considered essential for shaping long-term health outcomes.
Traditionally known for maintaining calcium balance and preventing skeletal disorders like Rickets, vitamin D is now recognized for broader biological effects. The review highlights that vitamin D influences over 1,000 genes through the vitamin D receptor (VDR), suggesting roles in immune function, metabolism, and neurodevelopment.
The analysis included data from randomized controlled trials, observational studies, and meta-analyses. Findings showed that maternal vitamin D supplementation during pregnancy—particularly around 1,000 IU/day—can improve neonatal bone mineral content, with some benefits extending into childhood. However, the long-term clinical significance of these effects remains unclear.
In immune health, vitamin D supplementation was associated with a modest reduction in acute respiratory tract infections, especially at doses between 400–1,000 IU daily. However, this benefit was less evident in infants under one year, indicating that age and developmental stage may influence outcomes.
Observational studies also linked low maternal vitamin D levels to adverse birth outcomes, including low birth weight and small-for-gestational-age infants. Additionally, emerging research suggests vitamin D may influence epigenetic programming and placental gene expression, though these findings require further validation.
Despite strong biological plausibility, evidence for non-skeletal benefits remains inconsistent and context-dependent. Vitamin D deficiency is still widespread, particularly among pregnant women, making supplementation an important public health consideration.
Overall, the review supports vitamin D’s role in early-life development but emphasizes the need for more precise, long-term studies to clarify optimal dosing and its broader health impacts.
REFERENCE: Sortino, C., et al. (2026). Vitamin D: Nutritional Programming During the First 1000 Days of Life. Nutrients, 18(7), 1096. DOI: 10.3390/nu18071096, https://www.mdpi.com/2072-6643/18/7/1096
Researchers Say Short High-Intensity Activity May Protect Against Eight Major Health Conditions
A new study published in the European Heart Journal suggests that even short bursts of vigorous physical activity can significantly reduce the risk of multiple chronic diseases.
Researchers found that just a few minutes of intense, breathless activity each day may lower the risk of conditions such as Dementia, Type 2 Diabetes, cardiovascular disease, arthritis, liver disease, kidney disease, and chronic respiratory disorders.
The study, led by Minxue Shen from Central South University, analyzed data from over 96,400 participants in the UK Biobank. Participants wore wrist accelerometers for one week to capture all physical activity, including short, often overlooked bursts of vigorous movement. Researchers then tracked health outcomes over seven years.
Results showed that individuals who engaged in higher levels of vigorous physical activity (VPA)—defined as activities that cause breathlessness—had 29% to 61% lower risks of developing major health conditions compared to those who did none.
The most striking findings included a 63% lower risk of dementia, a 60% reduction in type 2 diabetes, and a 46% lower risk of death among those with the highest activity levels.
Vigorous activity appears to trigger unique physiological responses. It improves heart efficiency, enhances blood vessel flexibility, and boosts the body’s ability to use oxygen. It may also stimulate brain chemicals that protect nerve cells, helping explain its strong link to reduced dementia risk.
Additionally, intensity plays a key role in lowering inflammatory conditions such as arthritis.
Importantly, benefits were seen with as little as 15–20 minutes of vigorous activity per week. Simple actions like brisk walking, climbing stairs quickly, or active play can make a meaningful difference, highlighting the value of incorporating short, intense movements into daily routines.
REFERENCE: Jiehua Wei, Minxue Shen, Shenxin Li, Yi Xiao, Dan Luo, Gerson Ferrari, Dong Hoon Lee, Leandro F M Rezende, Jason M R Gill, Matthew N Ahmadi, Emmanuel Stamatakis, Xiang Chen. Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases. European Heart Journal, 2026; DOI: 10.1093/eurheartj/ehag168


